APA (7th ed.) Citation

Franz, D. N., & Witt, O. (2014). Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. The lancet. Oncology, 15(13), . https://doi.org/10.1016/S1470-2045(14)70489-9

Chicago Style (17th ed.) Citation

Franz, David N., and Olaf Witt. "Everolimus for Subependymal Giant Cell Astrocytoma in Patients with Tuberous Sclerosis Complex: 2-year Open-label Extension of the Randomised EXIST-1 Study." The Lancet. Oncology 15, no. 13 (2014). https://doi.org/10.1016/S1470-2045(14)70489-9.

MLA (9th ed.) Citation

Franz, David N., and Olaf Witt. "Everolimus for Subependymal Giant Cell Astrocytoma in Patients with Tuberous Sclerosis Complex: 2-year Open-label Extension of the Randomised EXIST-1 Study." The Lancet. Oncology, vol. 15, no. 13, 2014, https://doi.org/10.1016/S1470-2045(14)70489-9.